Fatal gastrointestinal toxicity with ipilimumab after BRAF/ MEK inhibitor combination in a melanoma patient achieving pathological complete response
Metrics: PDF 1845 views | HTML 2439 views | ?
Maria Gonzalez-Cao1, Aram Boada2, Cristina Teixidó1,10, María Teresa Fernandez-Figueras3, Clara Mayo1,10, Francesc Tresserra4, Jean Bustamante5, Santiago Viteri1, Enrique Puertas6, Mariacarmela Santarpia7, Aldo Riso1, Feliciano Barron8, Niki Karachaliou1, Rafael Rosell1,9
1Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain
2Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
3Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
4Pathology Department, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain
5Albert Einstein Medical Center, Philadelphia, PA, USA
6Radiotherapy Department, Hospital Quirónsalud, Barcelona, Spain
7Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy
8Medical Oncology Unit, Insituto Nacional de Cancerología, México
9Catalan Institute of Oncology, Cancer Biology & Precision Medicine Programme, Germans Trias i Pujol Hospital and Health Sciences Institute, Badalona, Spain
10Pangaea Biotech, Laboratory of Oncology, Barcelona, Spain
Maria Gonzalez-Cao, email: firstname.lastname@example.org
Keywords: BRAF mutation, ipilimumab, melanoma, sequential treatment, toxicity
Received: April 03, 2016 Accepted: May 29, 2016 Published: July 18, 2016
Approximately 50% of metastatic melanoma patients harbor BRAF mutations. Several treatment options including the combination of BRAF and MEK inhibitors (BRAF/MEKi) and immunotherapy (mainly anti CTLA-4 and anti PD-1 antibodies), have been shown to improve survival in these patients. Although preclinical data support the synergistic effect of both modalities in combination, data confirming the activity and tolerability of these combinations are not yet available in the clinical setting. Herein, we report the case of a melanoma patient treated with sequential BRAF/MEKi (dabrafenib plus trametinib) followed by the anti CTLA-4 antibody ipilimumab who achieved a pathological complete response. Unfortunately, the patient died due to fatal gastrointestinal (GI) toxicity. Analysis of the BRAFV600E mutation in circulating tumoral DNA (ctDNA) from peripheral blood samples and serial tumor tissue biopsies throughout treatment demonstrated a good correlation with clinical evolution.
In recent years, several drugs have been approved for the treatment of patients with advanced stage melanoma harboring BRAF mutations. Two main treatment strategies have been shown to improve survival: the combination of targeted inhibitors of BRAF (such as dabrafenib or vemurafenib) and MEK (like trametinib or cobimetinib) [1-5] and the use of antibodies against immune checkpoint inhibitors like CTLA-4 (ipilimumab) [6-9] or PD-1 (pembrolizumab and nivolumab) [10-13]
Treatment with immunotherapy achieves unprecedented long survival rates, with a 3-year survival rate of 20-40% . Ipilimumab was the first approved immunotherapy drug based on an improvement in overall survival due to long term clinical benefit in a minority of patients . In the case of BRAF mutant melanoma patients, treatment with BRAF/MEKi has also demonstrated improvements in survival [2, 3, 8]. BRAF/MEKi achieves a high response rate, with activity in nearly 80% of patients [2, 3, 8]. Despite these rapid and frequent responses, the benefits of BRAF/MEKi are usually transient, with a median disease-free survival of less than 12 months because of the almost universal development of acquired resistance [2, 6, 14]. Therefore, interest in combining both treatment modalities—MAPK pathway inhibition and immunotherapy—has grown, with the goal of achieving improved long-term survival rates [15-19].
It remains controversial as to which of these treatments should be used in first-line setting [20, 21] and whether combining them (either simultaneously or sequentially) could improve their activity [17, 19]. Preclinical data support the use of sequential immunotherapy in tumors responding to BRAF/MEKi rather than waiting until progression has occurred following BRAF/MEKi treatment [22, 23]. BRAF/MEKi can produce changes in the tumoral microenvironment of responding lesions, which can then favor a response to immunotherapy [17, 23]. An increase in tumor infiltration by CD8+ lymphocytes with a decrease in regulatory T cells (Tregs) and other immunosuppressive cells, as well as an increase in PD ligand (PD-L1) expression on tumor cells, have also been observed in tumors responding to BRAF/MEKi . However, no clinical data are available that support the use of the sequential treatment in this setting.
What follows is a case report of fatal gastrointestinal (GI) toxicity in a melanoma patient who achieved a complete response (CR) with the combination of dabrafenib and trametinib followed by ipilimumab.
The patient was a 63-year-old man with no significant medical history. In November 2013, he visited the traumatology department owing to cervical pain. Magnetic resonance imaging (MRI) showed a lytic lesion at the C7 vertebrae with infiltration of both pedicles, raising suspicions of bone metastases. The PET-CT showed two hypermetabolic lesions, one at C7 (SUV 6.1) and another at D9 vertebrae (SUV 4.9), without visceral spread (Figure 1). On physical examination, a heterogeneous, hyperpigmented, three centimeter cutaneous lesion was found on the left parieto-occipital area of the scalp, consistent with primary melanoma. Core biopsy of the lesion at D9 vertebrae confirmed infiltration by melanoma cells, positive for both S-100 and HMB45 by immunohistochemistry (Figure 2). Routine blood tests showed no relevant data except high lactate dehydrogenase (LDH) levels. BRAFV600E mutation was detected in both tumoral tissue and circulating tumoral DNA (ctDNA) obtained from peripheral blood. In April 2014, the patient started treatment with dabrafenib (150 mg twice daily) in combination with trametinib (2 mg once daily), with rapid clinical improvement, depigmentation of the primary cutaneous lesion (Supplementary Figure 1), and negativization of the BRAFV600E mutation in ctDNA (Figure 1). In May 2014, after two weeks of treatment with BRAF/MEKi, a cervical vertebrectomy was performed to avoid neurological complications, followed by the surgical resection of the primary cutaneous lesion four weeks later. Surgical specimens confirmed melanoma infiltration at the bone lesion (Figure 3A and Supplementary Figure 2A-2B) with low CD8+ lymphocyte infiltration (Figure 3B) and negative PD-L1 immunohistochemistry (Figure 3C). Four weeks later, a complete melanoma regression without fibrosis at the primary site (Figure 3D) with an intense CD8+ infiltration (Figure 3E) and PD-L1-positive infiltrating lymphocytes (Figure 3F) was identified. In July 2014, a PET-CT showed a complete morpho-metabolic response (Figure 1). Treatment with dabrafenib and trametinib was stopped in July 2014 to perform radiotherapy of the bone lesions for consolidation therapy (30 Gy, 6 Gy/fraction). Treatment with ipilimumab 3 mg/kg intravenously (i.v.) and radiotherapy was started on August 2014. After the second dose of ipilimumab, the patient developed diarrhea, but he did not come to the hospital as he was instructed to do. After ten days of progressive deterioration with more frequent diarrhea and abdominal pain, the patient was finally admitted to the hospital. He presented with an acute abdomen with a perforated colon. Subtotal colectomy was performed, and pathological examination showed intestinal necrosis with increased lymphocyte infiltration in the wall, leading to a diagnosis of enterocolitis (Figure 4 and Supplementary Figure 3). The patient was admitted to the intensive care unit, and a high dose of corticosteroid treatment was administered. CT scan showed no metastatic lesions, while BRAFV600E mutation analysis in ctDNA showed negative results, even though there was a temporary peak of BRAFV600E in ctDNA four weeks after the last dose of ipilimumab. After eight weeks, the patient presented with a new colon perforation, even though corticosteroid treatment had been maintained. He and his family refused further treatment and opted for palliative care. Autopsy showed peritonitis with colon perforation and enterocolitis as the cause of the death (Supplementary Figure 4A); lung aspergilloma was also found (Supplementary Figure 4B). No melanoma metastases were found in the bones or at visceral sites, confirming a pathological CR (Figure 3G) with infiltration by CD8+ PD-L1-negative lymphocytes (Figure 3H and 3I).
Figure 1: Summary of evolution: correlation of clinical data and BRAFV600E determination on serial ctDNA analysis: determination of BRAFV600 on ctDNA correlated well with clinical evolution. A rapid negativization was observed 4 weeks after starting BRAF/MEKi. A peak after surgery of the bone metastases was observed, but it was transitory. After the first dose of ipilimumab, a transitory increase was also observed. Positron emission tomography (PET)-computed tomography (CT) demonstrated a complete response (CR) to dabrafenib and trametinib combination.
Abbreviations: ctDNA: circulating tumoral DNA; pCR: pathological complete response;
Figure 2: Core-biopsy of osteolithic lesion in the D9 vertebra showing bone infiltration by proliferation of round cells with hyperchromatic nucleus and occasional prominent nucleoli A. The immunohistochemical stains for HMB-45 B. and S-100 C. were positive.
Figure 3: Serial tissue biopsies. A, B, C: bone biopsy after two weeks on BRAF/MEKi treatment. A. Bone infiltration of C7 vertebra by a solid proliferation or round cells; B. Low CD8+ lymphocyte infiltration at bone metastases; C. negative programmed death-ligand (PD-L)1 immunohistochemistry at the bone lesion. D, E, F: primary cutaneous melanoma after six weeks on BRAF/MEKi treatment. D. pathological CR on primary cutaneous lesion, without fibrosis, after 6 weeks of treatment with BRAF/MEKi; E. intense CD8+ infiltration at the primary site; F. PD-L1 positivity on infiltrating lymphocytes at the primary tumor biopsy. G, H, I: bone biopsy from autopsy, after ipilimumab treatment. G. Body of the D9 vertebra with extensive fibrotic tissue with no residual tumor at autopsy; H. scanty lymphocytic infiltrate at bone (autopsy); I. PD-L1 negative at bone lesion (autopsy).
Figure 4: Subtotal colectomy. Enterocolitis due to ipilimumab. Large bowel wall with necrosis and lymphocytic and leucocytic infiltration.
Among the immune-related adverse events (irAEs) caused by ipilimumab treatment, GI toxicity is the most frequent. Around 20-30% of patients treated with ipilimumab in clinical trials [8, 24] and in the clinical setting  present with GI toxicity. Early treatment of this complication has been shown to be very important in avoiding life-threatening complications, such as the bowel perforation that occurred in this patient . In the first published phase III trial of ipilimumab in metastatic melanoma, five of 511 patients treated with ipilimumab died owing to bowel perforation . However, in more recent studies, no fatal adverse events related to ipilimumab have been reported, with severe colitis or diarrhea in only 7.7% and 4.5% of patients, respectively . This decrease in toxicity rate over time reflects a learning curve in the management of ipilimumab toxicity.
In our patient, the most probable cause of this fatal complication was the delay in communicating and treating GI symptoms. Other possible factors that could have increased the risk of complications were the concomitant treatment with radiotherapy or the previous treatment with the combination of BRA/MEKi.
A previous published case report described how radiotherapy in combination with ipilimumab shows marked activity via the so-called abscopal effect . According to data from a phase I trial, radiotherapy increases cancer antigen presentation due to tumor necrosis and enhances the diversity of the T cell receptor (TCR) in intratumoral cells, without increasing toxicity when combined with ipilimumab .
Treatment with ipilimumab following BRAF inhibitors has been previously reported in patients progressing to the targeted inhibitor . In this setting, no increase in toxicity was found . The possibility that ipilimumab is more toxic in patients achieving response than in those progressing to BRAF inhibitors is unlikely, but clinical trials ongoing will clarify this issue. Here, ipilimumab treatment was initiated in a responding melanoma, instead of waiting until progression, because both the patient’s preference for stopping oral drugs and trying a “definitive” treatment, and because radiotherapy requires interruption of BRAF/MEKi treatment in order to avoid toxicity.
The GI tract is a site of high immune system activity. The resident microbiota contain thousands of different bacteria that play an important role in lymphocyte education, with possible value as predictive markers of response  and toxicity to ipilimumab . Lymphocytes and other immune cells on the intestinal wall (mucosal associated lymphoid tissue, MALT) are very complex and include different innate and adaptive immune cells, including the largest population of T cells in the body. Most of these lymphocytes are CD4+, but other subsets of lymphoid cells, such as TH17 cells, CD8+Tregs, natural killer (NK) cells, and others, are also present . It is possible that lymphocytes infiltrating the bowel wall could be activated by ipilimumab in a non-standard manner after increasing their checkpoint inhibitor membrane presentation with a MEK inhibitor .
In the clinical setting, several phase I trials have reported toxicity related to the combination of BRAF/MEKi and ipilimumab. A trial testing the BRAF inhibitor vemurafenib plus ipilimumab was stopped owing to hepatotoxicity . The combination of dabrafenib plus trametinib and ipilimumab produced colon perforation in two of the seven patients treated in the phase I trial, while no toxicity was observed when trametinib was not included in the combination .
The present case had a CR with sequential BRAF/MEKi followed by ipilimumab. CR by PET-CT was observed after dabrafenib plus trametinib, as well as negativization of BRAFV600E mutation in ctDNA. Achieving CR to dabrafenib and trametinib combination is unusual (less than 10% of patients achieve a CR) , although the low tumor burden of this particular case could be the reason for this extraordinary response.
Although pathological CR assessed in the autopsy could be due exclusively to the dabrafenib and trametinib combination, and not necessarily to sequential treatment with ipilimumab, preclinical data suggest that immunotherapy could be more active in patients responding to BRAF/MEKi, instead of delaying treatment until MAPK inhibitor resistance occurs . Following a response to MAPK pathway inhibition, there is an increase in PD-L1 expression on tumor cells and a higher lymphocytic infiltration (CD8/CD4), as well as, a decrease in Treg infiltration and immunosuppressive cytokines (IL6, IL10, VEGF) [5, 35]. In addition, melanosomal antigen expression is higher following increased microphthalmia-associated transcription factor MITF levels owing to blockade of the MAPK pathway. Conversely, when tumors progress to BRAF inhibitors, MITF is downregulated and melanosomal antigen expression is decreased. Due to the paradoxical activation of the MAPK pathway in T cells by BRAF inhibitor, functionality is increased in T cells. Although there are reports of higher expression of PD-L1 in human biopsies after progression to BRAF inhibitors , this is not universally observed, and preclinical data in cell lines have demonstrated that its occurrence depends on the resistance mechanism . Given that resistance mechanisms are heterogeneous intra-patient and intra-lesion, PD-L1 expression in tissues after progression to BRAF inhibitors will be variable and weaker than in responding lesions. In our patient, after six weeks of treatment with BRAF/MEKi, an increase in CD8+ PD-L1+ lymphocyte infiltration was found at the cutaneous primary melanoma in complete regression (Figure 3D-3F), whereas there was no infiltration by CD8+ cells on bone metastases biopsy performed two weeks after starting BRAF/MEKi (Figure 3A-3C). After ipilimumab treatment, a moderate CD8+ PD-L1-lymphocyte infiltration was found at bone metastases with no residual tumor infiltration (Figure 3G-3I). It is possible, however, that the immunohistochemistry analysis for PD-L1 yielded false negative results because of the decalcification of the tissue sample (Figure 3I).
Recent data demonstrated that long-term survival is 20% after dabrafenib and trametinib combination treatment (progression-free survival [PFS] at three years of 21%). Survival is especially high in patients with normal pretreatment LDH levels or patients who achieve CR, with an overall survival (OS) in this subset at three years of 62% . It could be possible to treat successfully those patients who achieve a CR to dabrafenib and trametinib without any additional combinations. Clinical and molecular predictive factors that help to select the best treatment options for every case are urgently needed.
We have developed a reverse transcription polymerase chain reaction (RT-PCR) based assay to analyze and quantify BRAFV600E mutation in plasma and serum with a sensitivity level of 0.005% mutation load. In our experience, about 70% of BRAF metastatic melanoma patients have a detectable mutation on pretreatment ctDNA, and those patients with detectable BRAFV600E mutation on ctDNA pretreatment have a poor outcome, with a median OS of 7 months versus 22 months for those without pretreatment BRAFV600E mutation on ctDNA . In addition, we have observed that 60% of patients with a BRAF mutation in pretreatment plasma/serum samples achieved BRAF ctDNA negativization during treatment . Poor outcomes have been observed in those patients with persistence of BRAF mutation in blood after the first weeks on treatment, with rapid disease progression leading to death within a few months .
In the present case, the BRAFV600E mutation was detected in the pretreatment plasma sample, in spite of the low tumor burden. A rapid decrease was observed after dabrafenib and trametinib combination, with a complete negativization achieved in four weeks. After surgery of the metastatic bone lesion, a temporary increase in BRAFV600E ctDNA was found. It is well known that this phenomenon is due to the release of DNA into the blood after trauma or surgical procedures. A transitory peak of BRAFV600E ctDNA after ipilimumab treatment was observed, and although a false positive result cannot be ruled out, this finding suggests a transitory progression of the disease with a final response to ipilimumab, as response to immunotherapy needs more time to activate the immune response. Our group has demonstrated that monitoring disease evolution by BRAF ctDNA analysis during treatment has a good correlation with clinical evolution and could help us assess response to therapy before it is detected by conventional imaging techniques .
Ipilimumab-associated fatal toxicities are observed mainly in cases wherein management of toxicity is delayed, as in the present case.
Combination modalities with sequential or concomitant BRAF/MEKi and ipilimumab must be carefully evaluated in the context of clinical trials, given that several cases of colon perforation have been reported with the combination of MEK inhibitors and ipilimumab .
It is known that some prognostic factors, such as normal LDH levels or CR, predict a good evolution with simple treatments like BRAF/MEK inhibitor combination . Identifying prognostic and predictive factors will help select those patients who need more aggressive treatments and those who can achieve long-term survival using less complex treatments.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
1. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386: 444-51.
2. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, et al. Overall survival and durable responses in patients With BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016; 10: 871-8.
3. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372: 30-9.
4. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371: 1867-76.
5. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B., Lewis K, Kee D, Boasberg P, Yin M, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014; 15: 954-65.
6. Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015; 33: 1191-6.
7. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data From phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; 33: 1889-94.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.
9. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013; 19: 2232-9.
10. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372: 320-30.
11. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-33.
12. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SJ, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16: 908-18.
13. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521-32.
14. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015; 16: 1389-98.
15. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012; 72: 3928-37.
16. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015; 21: 1639-51.
17. Cooper ZA, Reuben A, Amaria RN, Wargo JA. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology. 2014; 3: e954956.
18. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014; 2: 643-54.
19. Donia M, Fagone P, Nicoletti F, Andersen RS, Hogdall E, Straten PT, Andersen MH, Svane IM. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012; 1: 1476-83.
20. Ascierto PA, Margolin K. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. Cancer. 2014; 120: 1617-9.
21. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest. 2014; 32: 144-9.
22. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19: 1225-31.
23. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012; 18: 1386-94.
24. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-26.
25. Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, Butler MO, Joshua AM. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology Lett. 2016; 11: 1581-5.
26. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 1270-1.
27. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366: 925-31.
28. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520: 373-7.
29. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350: 1079-84.
30. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016; 7: 10391.
31. Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunological reviews. 2013; 252: 164-82.
32. Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS. The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. Oncoimmunology. 2014; 3:e946367.
33. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013; 368: 1365-6.
34. Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015; 28: 611-2.
35. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015; 7: 279ra41.
36. Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. PLoS ONE. 2015; 10: e0123410.
37. Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Munoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015; 25: 486-95.
38. Gonzalez-Cao M, Manzano JL, Soriano V, Casas CMdl, Puertolas T, Soria A Molina-Vila MA, Majem M, Montagut C, Muñoz E, Rodríguez D, Perez E, Garcia A, et al. BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group) AACR Annual Meeting 2016 in New Orleans, Louisiana 2016; Abstract 468.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.